Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + vorinostat
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
The combination of **paclitaxel**, **carboplatin**, and **vorinostat** is an investigational chemotherapeutic regimen used in clinical trials for cancer. Paclitaxel is a microtubule-stabilizing agent (taxane class), carboplatin is a DNA-damaging platinum agent, and vorinostat is a histone deacetylase (HDAC) inhibitor. Vorinostat enhances the anticancer effects of platinum compounds and taxanes by inducing chromatin remodeling, increasing DNA damage, and modulating gene expression, both through histone and nonhistone-mediated mechanisms. Clinically, this combination has been evaluated in phase II studies in patients with **advanced non-small-cell lung cancer (NSCLC)** and **platinum-sensitive recurrent ovarian, peritoneal, or fallopian tube carcinoma**, demonstrating improved response rates, tolerable safety profiles, and promising survival outcomes compared to carboplatin plus paclitaxel alone[1][2][3][4].
- Brand names
- ZolinzaTaxolParaplatin
- Other names
- suberoylanilide hydroxamic acid + paclitaxel + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAHDAC (HDAC family)
Beyond the preview
Go deeper on paclitaxel + carboplatin + vorinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + vorinostat.